Boston Partners
AMPH icon

Boston Partners’s Amphastar Pharmaceuticals AMPH Stock Holding History

Boston Partners’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-423,070
Closed -$11.9M – 712
2025
Q1 		$11.9M Sell
423,070
-3,566
-0.8% -$114K 0.01% 372
2024
Q4 		$15.8M Buy
+426,636
New +$19.5M 0.02% 353

Other funds holding AMPH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
EIP
Epoch Investment Partners New York $17.6B AUM 34.17% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Boston Partners's AMPH Position: Q2 2025 in Review

Boston Partners sold out of Amphastar Pharmaceuticals (AMPH) in Q2 2025, closing a stake of 423,070 shares — an estimated $11.9M sold.

Boston Partners first reported a position in AMPH in Q4 2024 and held it in 2 quarters. The position peaked at $15.8M in Q4 2024. 245 funds tracked by Wall St. Rank hold AMPH as of Q2 2025.

  • Boston Partners reported no remaining Amphastar Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Boston Partners sold 423,070 Amphastar Pharmaceuticals shares in Q2 2025, an estimated $11.9M.
  • Boston Partners first reported a position in Amphastar Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Boston Partners's Amphastar Pharmaceuticals position peaked at $15.8M in Q4 2024.
  • 245 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q2 2025.

Based on Boston Partners's 13F filing for Q2 2025, filed 7 Aug 2025.